PROK — PROKIDNEY CORP.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1850270 ·
Last close
$1.75
Market Cap
$359.10M
52W High
$2.19
52W Low
$1.53
ADV30
935,846
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 226,000 | — | -44,933,000 | -20,037,000 | 292,784,000 | 101,895,000 | 29,680,000 |
| Dec 2025 | 225,000 | — | -45,371,000 | -19,231,000 | 335,574,000 | 108,537,000 | 34,781,000 |
| Sep 2025 | 217,000 | — | -38,539,000 | -16,469,000 | 351,608,000 | 95,323,000 | 33,270,000 |
| Jun 2025 | 221,000 | — | -39,709,000 | -16,552,000 | 372,133,000 | 84,940,000 | 32,680,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-132,209,000
Investing CF
$110,503,000
Financing CF
$25,796,000
CapEx
$-17,846,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.52
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,289,872,000
Inventory
—
Receivables
$1,032,000
ST Investments
$123,049,000
EBIT TTM
$-156,439,000
Pretax Income TTM
$-156,458,000
Interest Exp TTM
$19,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$889,000
EBITDA
$-161,919,008
Free Cash Flow
$-78,626,872
Enterprise Value
$1,412,513,536
Total Cash
$224,944,000
Total Debt
$3,783,000
Shares Out
205,199,713
Trailing EPS
$-0.53
Book Value
$-7.21
ROE
-49.4%
ROA
-30.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 893,000 | -165,007,000 | -68,986,000 | 335,574,000 | 34,781,000 | — | -120,117,000 |
| Dec 2024 | 76,000 | -183,676,000 | -61,186,000 | 441,073,000 | 39,436,000 | — | -126,351,000 |
| Dec 2023 | 0 | -151,522,000 | -35,468,000 | 420,552,000 | 29,216,000 | — | -90,069,000 |
| Dec 2022 | 0 | -153,007,000 | -108,032,000 | 517,996,000 | 13,057,000 | — | -77,089,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.58
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $1.75 · call volume: 256 · put volume: 1Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CMPX | Compass Therapeutics, Inc. | $369.18M | $2.05 | — |
| ZURA | Zura Bio Ltd | $343.47M | $3.62 | — |
| XFOR | X4 Pharmaceuticals, Inc | $381.99M | $4.05 | — |
| LXEO | Lexeo Therapeutics, Inc. | $391.04M | $4.98 | — |
| EDIT | Editas Medicine, Inc. | $391.33M | $2.55 | — |
News headlines (Yahoo Finance, 1h cache)
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path
2026-06-17 15:16 · Yahoo
Identiv And Two Other Penny Stocks To Watch Closely
2026-06-05 18:15 · Yahoo
ProKidney Appoints Kenneth Locke as Chief Technical Officer
2026-06-02 12:00 · Yahoo
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
2026-05-15 16:55 · Yahoo
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-15 15:45 · Yahoo
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
2026-05-15 11:10 · Yahoo
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
2026-05-14 12:45 · Yahoo
3 Promising Penny Stocks With Market Caps Up To $600M
2026-05-06 18:05 · Yahoo
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel
2026-05-01 09:23 · Yahoo
April 2026 Penny Stock Highlights
2026-04-03 18:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.